Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pro MedicusPMDIY 77 Debt-to-EBITDA is 0.01 as of Dec. 2025, which is 67% below its 10-year median of 0.03. GuruFocus rates PMDIY with a GF Score™ of 77/100 and a GF Value™ of $40.14 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 477 Healthcare Providers & Services companies, Pro Medicus ranks better than 99.79% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Pro Medicus's Debt-to-EBITDA or its related term are showing as below:
PMDIY'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01 Med: 0.03 Max: 0.06
Current: 0.01
During the past 13 years, the highest Debt-to-EBITDA Ratio of Pro Medicus was 0.06. The lowest was 0.01. And the median was 0.03.
PMDIY's Debt-to-EBITDA is ranked better than 99.79% of 477
companies
in the Healthcare Providers & Services industry
Industry Median: 2.22
vs PMDIY: 0.01
Pro Medicus (OTCPK:PMDIY) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Pro Medicus Debt-to-EBITDA Related Terms
Pro Medicus Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Pro Medicus's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PMDIY vs VEEV, BTSG, TEM: Debt-to-EBITDA Comparison
For the Health Information Services subindustry, Pro Medicus's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pro Medicus Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pro Medicus's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Pro Medicus's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Pro Medicus (PMDIY) has a Debt-to-EBITDA of 0.01 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Pro Medicus. This is 67% below median its historical median of 0.03. Over the past decade, Pro Medicus' Debt-to-EBITDA has ranged from 0.01 to 0.06. According to the industry distribution chart, Pro Medicus ranks #1 out of 477 companies in the Healthcare Providers & Services industry, placing it in the top 0.2%.
Is Pro Medicus' Debt-to-EBITDA too high?
Pro Medicus' current Debt-to-EBITDA of 0.01 is 67% below median its 10-year median of 0.03. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.06. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.22. Pro Medicus' value of 0.01 is 99.5% below this industry median. Based on the distribution chart, Pro Medicus ranks #1 out of 477 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Pro Medicus has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pro Medicus' Debt-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Pro Medicus ranks #1 out of 477 companies for Debt-to-EBITDA. This places Pro Medicus in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.22. Pro Medicus' value of 0.01 is 99.5% below this benchmark. Historically, Pro Medicus' own Debt-to-EBITDA has ranged from 0.01 to 0.06 over the past decade. While the company's 10-year median is 0.03 vs. the industry median of 2.22, Pro Medicus has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.22, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pro Medicus's current Debt-to-EBITDA of 0.01 is 99.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Pro Medicus. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pro Medicus's current Debt-to-EBITDA is 0.01, which is 67% below median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pro Medicus stock overvalued right now?
Based on GuruFocus' analysis, Pro Medicus (PMDIY) is currently considered Modestly Undervalued. The stock's GF Value™ is $40.14, compared to a current price of $29.51 — trading 26.5% below its estimated fair value. The current Debt-to-EBITDA is 0.01, which is 67% below median its 10-year median of 0.03 and 99.5% below the Healthcare Providers & Services industry median of 2.22. Pro Medicus' overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Pro Medicus (PMDIY), the current Debt-to-EBITDA is 0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pro Medicus (PMDIY) Overvalued in 2026?
Based on GuruFocus' analysis, Pro Medicus stock appears to be undervalued.
The current stock price of $29.51 is trading 26.5% below its estimated GF Value™ of $40.14.
GuruFocus considers Pro Medicus to be Modestly Undervalued.
Key valuation signals for PMDIY:
Debt-to-EBITDA: 0.01 (67% below median its 10-year median of 0.03)
GF Value™: $40.14 vs. price of $29.51 (26.5% below fair value)
Industry Position: 99.5% below the Healthcare Providers & Services median (#1 of 477)
No single metric tells the full story. See the PMDIY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2025, Pro Medicus earned 90% of revenue in North America, 8% from Australia, and the remaining 2% in Europe.
77GF Score
Get the complete analysis for PMDIY
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMDIY has been successfully added to your 
